Virus Vectors Articles & Analysis
11 news found
In recent years, applications of viral vectors have found an encouraging new beginning in gene therapy and in vaccine development. What can viral vectors be used for? Substantial improvements in viral vector manufacturing, delivery, and safety have placed viral vector-based therapy at the forefront of modern medicine. Viral vectors can be used for the treatment of various ...
ByNuvonis
Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, will be featured in a live webinar to be held on Monday, November 14, 2022, at 2:30pm EST. This webinar will focus on process intensification in the manufacturing of adeno associated virus (AAV) vectors. AAV vectors are critical to gene therapy development. These vectors are the delivery ...
ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases ViGeneron GmbH, a next-generation gene therapy company, ...
Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exclusive license to develop and commercialize the gene therapy product ViGeneron is eligible to receive upfront payment, research funding, option exercise fee, development and commercial milestone payments, plus royalties on net sales The collaboration further validates ...
The human body consists of trillions of cells, each possessing their own copy of DNA that provides the blueprint for making a human. Despite sharing the same DNA, different cells activate a varied mix of genes within them to enable differentiation into various tissues and organs. For millions of people, unfortunately, some of these genes do not function properly, resulting in diseases and ...
ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmic disease. ViGeneron’s vgAAVs enable the efficient transduction ...
Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target The companies will use ViGeneron’s proprietary vgAAV technology to efficiently transduce target cells via intravitreal injections ViGeneron GmbH, a gene therapy company, today announced a global collaboration and licensing agreement with Biogen ...
BERLIN, GERMANY, and SOMERSET, N.J. – September 21, 2020 — T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, ...
BlueSky Immunotherapies has expanded and secured its intellectual property portfolio. The patents based on WO2015/063085 cover a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein and forms the basis of the company’s technology platform. Corresponding patents were recently granted in (EP 3063273), USA (US 10480013), and China (CN 2019112100112140) ...
USPOULTRY and the USPOULTRY Foundation announce the completion of a funded research project at North Carolina State University in Raleigh, N.C., that evaluated a new vaccine to protect again two important diseases. The project is part of the Association’s comprehensive research program encompassing all phases of poultry and egg production and processing. A brief summary of the completed ...
Africa needs more research to address the information gaps on the impact of climate change on diseases, infections and epidemics caused by plant viruses, according to a study. Researchers at the University of Western Australia conducted a review of existing literature, and found that the research gaps include a lack of climate change-scenario modelling for diseases caused by plant viruses, and ...